Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy

Next Previous
Search
Trial Profile

A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pyrotinib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Salivary gland cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Hengrui Therapeutics; Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 28 Jan 2021 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.
    • 28 Jan 2021 Planned primary completion date changed from 30 Sep 2020 to 1 May 2021.
    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top